High Serum Alkaline Phosphatase, Hypercalcaemia, Race, and Mortality in South African Maintenance Haemodialysis Patients

Overview

Journal Int J Nephrol

Publisher Wiley

Specialty Nephrology

Date 2017 Feb 8

PMID 28168054

Citations 7

Authors

Bala Waziri

Raquel Duarte

Saraladevi Naicker

Affiliations

Soon will be listed here.

Abstract

To determine the association between serum total alkaline phosphatase (TAP) and mortality in African maintenance haemodialysis patients (MHD). The study enrolled a total of 213 patients on MHD from two dialysis centers in Johannesburg between January 2009 and March 2016. Patients were categorized into a low TAP group (≤112 U/L) versus a high TAP group (>112 U/L) based on a median TAP of 112 U/L. During the follow-up period of 7 years, there were 55 (25.8%) deaths. After adjusting for cofounders such as age, other markers of bone disorder, and comorbidity (diabetes mellitus), patients in the high TAP group had significantly higher risk of death compared to patients in the low TAP group (hazard ratio, 2.50; 95% CI 1.24-5.01, = 0.01). Similarly, serum calcium >2.75 mmol/L was associated with increased risk of death compared to patients within levels of 2.10-2.37 mmol/L (HR 6.34, 95% CI 1.40-28.76; = 0.02). The HR for death in white patients compared to black patients was 6.88; 95% CI 1.82-25.88; = 0.004. High levels of serum alkaline phosphatase, hypercalcaemia, and white race are associated with increased risk of death in MHD patients.

Citing Articles

Serum alkaline phosphatase and infection-related mortality in hemodialysis patients: ten-year outcomes of the Q-cohort study.

Kitamura H, Yotsueda R, Hiyamuta H, Taniguchi M, Tanaka S, Yamada S Clin Exp Nephrol. 2022; 26(11):1119-1129.

PMID: 35927603 DOI: 10.1007/s10157-022-02255-4.

Relationship between serum alkaline phosphatase and poor 3-month prognosis in acute ischemic stroke patients with preserved renal function: results from Xi'an Stroke Registry Study of China.

Liu Z, Lin X, Zeng L, Lu Q, Liu P, Wang J BMC Neurol. 2022; 22(1):249.

PMID: 35799136 PMC: 9260988. DOI: 10.1186/s12883-022-02779-y.

Risk factors affecting the 1-year outcomes of minor ischemic stroke: results from Xi'an stroke registry study of China.

Liu Z, Lin W, Lu Q, Wang J, Liu P, Lin X BMC Neurol. 2020; 20(1):379.

PMID: 33081723 PMC: 7574206. DOI: 10.1186/s12883-020-01954-3.

Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD): Current Perspectives.

Waziri B, Duarte R, Naicker S Int J Nephrol Renovasc Dis. 2020; 12:263-276.

PMID: 31920363 PMC: 6935280. DOI: 10.2147/IJNRD.S191156.

Associations of plasma fibroblast growth factor 23 and other markers of chronic kidney disease-Mineral and bone disorder with all-cause mortality in South African patients on maintenance dialysis: A 3-year prospective cohort study.

Waziri B, Musenge E, Duarte R, Dickens C, Dix-Peek T, Rekhviashvili V PLoS One. 2019; 14(5):e0216656.

PMID: 31107896 PMC: 6527219. DOI: 10.1371/journal.pone.0216656.

References

Regidor D, Kovesdy C, Mehrotra R, Rambod M, Jing J, McAllister C . Serum alkaline phosphatase predicts mortality among maintenance hemodialysis patients. J Am Soc Nephrol. 2008; 19(11):2193-203. PMC: 2573010. DOI: 10.1681/ASN.2008010014. View

Sigrist M, Taal M, Bungay P, McIntyre C . Progressive vascular calcification over 2 years is associated with arterial stiffening and increased mortality in patients with stages 4 and 5 chronic kidney disease. Clin J Am Soc Nephrol. 2007; 2(6):1241-8. DOI: 10.2215/CJN.02190507. View

Feroze U, Noori N, Kovesdy C, Molnar M, Martin D, Reina-Patton A . Quality-of-life and mortality in hemodialysis patients: roles of race and nutritional status. Clin J Am Soc Nephrol. 2011; 6(5):1100-11. PMC: 3087777. DOI: 10.2215/CJN.07690910. View

Shantouf R, Kovesdy C, Kim Y, Ahmadi N, Luna A, Luna C . Association of serum alkaline phosphatase with coronary artery calcification in maintenance hemodialysis patients. Clin J Am Soc Nephrol. 2009; 4(6):1106-14. PMC: 2689878. DOI: 10.2215/CJN.06091108. View

Lomashvili K, Garg P, Narisawa S, Millan J, ONeill W . Upregulation of alkaline phosphatase and pyrophosphate hydrolysis: potential mechanism for uremic vascular calcification. Kidney Int. 2008; 73(9):1024-30. PMC: 3010853. DOI: 10.1038/ki.2008.26. View

Schoppet M, Shanahan C . Role for alkaline phosphatase as an inducer of vascular calcification in renal failure?. Kidney Int. 2008; 73(9):989-91. DOI: 10.1038/ki.2008.104. View

ONeill W . Pyrophosphate, alkaline phosphatase, and vascular calcification. Circ Res. 2006; 99(2):e2. DOI: 10.1161/01.RES.0000234909.24367.a9. View

Beige J, Wendt R, Girndt M, Queck K, Fiedler R, Jehle P . Association of serum alkaline phosphatase with mortality in non-selected European patients with CKD5D: an observational, three-centre survival analysis. BMJ Open. 2014; 4(2):e004275. PMC: 3939663. DOI: 10.1136/bmjopen-2013-004275. View

Badve S, Zhang L, Coombes J, Pascoe E, Cass A, Clarke P . Association between serum alkaline phosphatase and primary resistance to erythropoiesis stimulating agents in chronic kidney disease: a secondary analysis of the HERO trial. Can J Kidney Health Dis. 2015; 2:33. PMC: 4538753. DOI: 10.1186/s40697-015-0066-5. View

10.

Floege J, Kim J, Ireland E, Chazot C, Drueke T, de Francisco A . Serum iPTH, calcium and phosphate, and the risk of mortality in a European haemodialysis population. Nephrol Dial Transplant. 2010; 26(6):1948-55. PMC: 3107766. DOI: 10.1093/ndt/gfq219. View

11.

Friedman A, Fadem S . Reassessment of albumin as a nutritional marker in kidney disease. J Am Soc Nephrol. 2010; 21(2):223-30. DOI: 10.1681/ASN.2009020213. View

12.

Fukagawa M, Kido R, Komaba H, Onishi Y, Yamaguchi T, Hasegawa T . Abnormal mineral metabolism and mortality in hemodialysis patients with secondary hyperparathyroidism: evidence from marginal structural models used to adjust for time-dependent confounding. Am J Kidney Dis. 2013; 63(6):979-87. DOI: 10.1053/j.ajkd.2013.08.011. View

13.

Blayney M, Pisoni R, Bragg-Gresham J, Bommer J, Piera L, Saito A . High alkaline phosphatase levels in hemodialysis patients are associated with higher risk of hospitalization and death. Kidney Int. 2008; 74(5):655-63. DOI: 10.1038/ki.2008.248. View

14.

Wolf M, Betancourt J, Chang Y, Shah A, Teng M, Tamez H . Impact of activated vitamin D and race on survival among hemodialysis patients. J Am Soc Nephrol. 2008; 19(7):1379-88. PMC: 2440300. DOI: 10.1681/ASN.2007091002. View

15.

Gutierrez O, Farwell W, Kermah D, Taylor E . Racial differences in the relationship between vitamin D, bone mineral density, and parathyroid hormone in the National Health and Nutrition Examination Survey. Osteoporos Int. 2010; 22(6):1745-53. PMC: 3093445. DOI: 10.1007/s00198-010-1383-2. View

16.

Lips P, Duong T, Oleksik A, Black D, Cummings S, Cox D . A global study of vitamin D status and parathyroid function in postmenopausal women with osteoporosis: baseline data from the multiple outcomes of raloxifene evaluation clinical trial. J Clin Endocrinol Metab. 2001; 86(3):1212-21. DOI: 10.1210/jcem.86.3.7327. View

17.

Lau W, Kalantar-Zadeh K . Towards the revival of alkaline phosphatase for the management of bone disease, mortality and hip fractures. Nephrol Dial Transplant. 2014; 29(8):1450-2. PMC: 4106643. DOI: 10.1093/ndt/gfu086. View

18.

Crews D, Sozio S, Liu Y, Coresh J, Powe N . Inflammation and the paradox of racial differences in dialysis survival. J Am Soc Nephrol. 2011; 22(12):2279-86. PMC: 3250209. DOI: 10.1681/ASN.2011030305. View

19.

Young E, Albert J, Satayathum S, Goodkin D, Pisoni R, Akiba T . Predictors and consequences of altered mineral metabolism: the Dialysis Outcomes and Practice Patterns Study. Kidney Int. 2005; 67(3):1179-87. DOI: 10.1111/j.1523-1755.2005.00185.x. View

20.

Hanley A, Williams K, Festa A, Wagenknecht L, DAgostino Jr R, Haffner S . Liver markers and development of the metabolic syndrome: the insulin resistance atherosclerosis study. Diabetes. 2005; 54(11):3140-7. DOI: 10.2337/diabetes.54.11.3140. View